Stock IMUX IMMUNIC, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Immunic, Inc.

Equities

IMUX

US4525EP1011

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
1.22 USD -3.17% Intraday chart for Immunic, Inc. +3.39% -18.67%
09/04 Transcript : Immunic, Inc. - Special Call
21/03 Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium MT

Evolution of the average Target Price on Immunic, Inc.

Price target over the last 5 years

History of analyst recommendation changes

237fe7b746eb0e.bSd7_3PB9hyB1iaukvTGvdQbrVQGZH8Qi03bdSIvCpQ.XW5CmDGRwS_0oXHp2oaj5Jw26xM2PSBCzhmoMxAfTsEdTQ21NZKHbsTuHg~b1b146f9be243d7084f362720a5ccda9

Analyst Recommendations on Immunic, Inc.

Wedbush Adjusts Immunic's PT to $4 From $7 on Increased Sharecount From First Tranche of Private Placemebt, Keeps Outperform Rating MT
Wedbush Adjusts Price Target on Immunic to $7 From $5, Maintains Outperform Rating MT
North American Morning Briefing: Treasury Yields Dive as Rate-Rise Fears Ease DJ
Wedbush Assumes Coverage of Immunic With Outperform Rating, Lowers Price Target to $5 From $7 MT
SVB Securities Downgrades Immunic to Market Perform From Outperform, Adjusts Price Target to $5 From $9 MT
Wedbush Adjusts Immunic's Price Target to $7 From $11 on Stock Dilution, Keeps Outperform Rating MT
Immunic, Inc. Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate CI
HC Wainwright Assumes Immunic at Buy with $26 Price Target MT
Wedbush Adjusts Immunic's Price Target to $11 From $14, Keeps Outperform Rating MT
SVB Securities Adjusts Immunic's Price Target to $9 From $45, Keeps Outperform Rating MT
Wedbush Adjusts Immunic's Price Target to $14 From $61, Removing IMU-838/Ulcerative Colitis From Model; Outperform Rating Kept MT
Piper Sandler Adjusts Immunic's Price Target to $39 From $71, Reiterates Overweight Rating MT
IMMUNIC : HC Wainwright Adjusts Immunic's Price Target to $25 from $40, Keeps Buy Rating MT
IMMUNIC : Wedbush Adjusts Immunic's Price Target to $61 From $68, Citing Stock Dilution; Outperform Rating Kept MT
IMMUNIC : Wedbush Trims Immunic's Price Target to $68 From $72 on Adjusted IMU-838/RRMS Timeline; Outperform Rating Kept MT
IMMUNIC : Aegis Capital Initiates Immunic at Buy Rating With $55 Price Target MT
IMMUNIC : JMP Securities Starts Immunic at Market Outperform With $55 Price Target MT
IMMUNIC : Wedbush Adjusts Immunic's Price Target to $72 From $67, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.22 USD
Average target price
11.5 USD
Spread / Average Target
+842.62%
High Price Target
28 USD
Spread / Highest target
+2,195.08%
Low Price Target
4 USD
Spread / Lowest Target
+227.87%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Immunic, Inc.

Wedbush
SVB Securities LLC
HC Wainwright
Piper Sandler
Aegis Capital
JMP Securities

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IMUX Stock
  4. Consensus Immunic, Inc.